Navigation Links
Cohera Medical Names Richard L. Wonsettler as Company's First CFO
Date:6/30/2008

PITTSBURGH, June 30 /PRNewswire/ -- Cohera Medical Inc. today named Richard L. Wonsettler to the newly created position of vice president of finance and CFO.

The addition of Wonsettler, who has nearly 20 years of financial management experience with emerging private and public companies, comes at a time that Cohera Medical is preparing to enter the clinical stage of development with its lead surgical adhesive product, TissuGlu(R).

"We are entering an important phase in the company's growth," said Patrick Daly, president and CEO of Cohera Medical. "In conjunction with our product development activities, we are ramping up our financing activities. Richard has the proven experience in working with companies in positions similar to ours. He will be integral to our plans moving forward."

Prior to joining Cohera Medical, Wonsettler was the CFO and treasurer of Active Media/ClubCom Inc., venture-capital-backed, start-up companies in Pittsburgh for which he built the accounting and treasury departments. Before this, Wonsettler worked with Wexford, Penn.-based SMT Health Services Inc. (SMT) as CFO and treasurer. He was the head of SMT's finance department when the company was owned by private equity firm Apollo Management L.P. Earlier in his career, Wonsettler was an audit professional with KPMG L.L.P. in Pittsburgh.

Wonsettler is a certified public accountant. He received a bachelor's degree in accounting, summa cum laude, from Washington and Jefferson College in Washington, Penn.

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
2. MYSTERY ER Season 2 Takes Viewers Behind the Curtain for Real-Life Medical Mysteries on Discovery Health
3. WaferGens SmartChip(TM) Real-Time PCR System to Begin Alpha Testing at University of Pittsburgh Medical School
4. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
5. Medical Machines Online Announces the Overstock and Release of a New ECG Machine
6. Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan
7. Grubb & Ellis Healthcare REIT Acquires SouthCrest Medical Plaza in Stockbridge, Ga.
8. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
9. Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement
10. Pathway Medical Technologies Awarded New Patent for Pathway PV(TM) Atherectomy System for Improved Differential Cutting
11. Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
Breaking Medicine Technology: